Mr. Xin Huang|Oncology Pharmaceuticals|Best Researcher Award

Mr. Xin Huang|Oncology Pharmaceuticals|Best Researcher Award

Mr. Xin Huang at Wuhan union hospital,China

PROFILE  

 

scopus

Orcid

Early Academic Pursuits 🎓

Dr. Xin Huang’s academic journey commenced at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, where their dedication to medical and research excellence became evident. Since September 2017, Dr. Huang has pursued a dual degree (M.D., Ph.D.), focusing on the nexus of clinical medicine and groundbreaking research. This rigorous training honed both clinical acumen and investigative prowess, laying the foundation for significant contributions to medical science. Their education encompassed advanced studies in bone and joint diseases, immune inflammation, and regenerative medicine, highlighting a strong commitment to tackling some of the most pressing challenges in healthcare.

Professional Endeavors 🩺

Dr. Xin Huang is currently an Attending Doctor at Union Hospital, Tongji Medical College. In this capacity, they seamlessly integrate patient care with research innovation. Beyond clinical practice, Dr. Huang has contributed to over 38 peer-reviewed publications in high-impact journals, reflecting a commitment to advancing medical knowledge.

Their professional engagements also include editorial roles on the Young Editorial Boards of journals like iMeta, Biomaterials Translational, and Gene Expression. These roles underscore their expertise and standing in the scientific community. Furthermore, Dr. Huang has expanded their horizons internationally through a visiting study at the University of Würzburg, Germany, fostering global collaboration in cutting-edge research.

Contributions and Research Focus 🔬

Dr. Huang’s research portfolio is both diverse and impactful. Their primary focus lies in targeted and precise treatment of bone tumors, particularly through an innovative approach centered on the tumor microenvironment (TME). Key areas of research include:

  • Tumor Microenvironment Exploration: Revealing the characteristics of the TME in bone tumors to understand how these environments support or hinder disease progression.
  • Immune Checkpoint Studies: Investigating immune checkpoints such as PD-L1 to discover how they can be manipulated for therapeutic purposes, especially in immunotherapy.
  • Biomimetic Nanovesicles: Pioneering the construction of biomimetic cell membrane-coated nanovesicles designed to deliver targeted anti-tumor treatments with high precision and minimal side effects.

This work has contributed to new paradigms in treating bone tumors and has significant implications for broader applications in oncology, regenerative medicine, and immunology.

Accolades and Recognition 🏆

Dr. Xin Huang’s dedication to research and patient care has been widely recognized. With 38 SCI/Scopus-indexed publications and three patents, Dr. Huang has firmly established themselves as a thought leader in their field. Their editorial appointments and membership in prestigious organizations such as the Chinese Medical Doctor Association and the Tumor Precision Therapy Professional Committee of the Chinese Anti-Cancer Association further attest to their standing in the academic and medical community.

Notably, Dr. Huang is a nominee for the Best Researcher Award, a testament to their relentless pursuit of excellence and innovation.

Impact and Influence 🌟

Dr. Huang’s work transcends academic circles, offering tangible benefits for patients and practitioners alike. By revealing the intricacies of the tumor microenvironment and advancing targeted treatments, they have paved the way for more effective therapies with fewer side effects.

Their contributions have also fostered international collaboration, bridging the gap between research communities in China and Europe. As an advocate for interdisciplinary research, Dr. Huang’s efforts have influenced emerging areas such as nanomedicine, tissue engineering, and immune-oncology.

Legacy and Future Contributions 🌍

Dr. Xin Huang’s legacy is one of innovation, compassion, and collaboration. As they continue their work in regenerative medicine and oncology, their future goals include:

  • Expanding Clinical Applications: Translating research findings into widely accessible treatments for bone tumors and related conditions.
  • Mentorship and Leadership: Inspiring the next generation of scientists and clinicians by serving as a mentor and role model.
  • Global Health Initiatives: Extending their expertise to address global health challenges, particularly in under-resourced settings.

In summary, Dr. Xin Huang’s journey is characterized by a commitment to excellence in medicine and science. Through their pioneering research, professional dedication, and collaborative spirit, they are poised to leave an enduring impact on the fields of oncology, regenerative medicine, and beyond.

🎓Publication 

Injectable hydrogels for Fenton-like Mn2+/Fe2+ delivery with enhanced chemodynamic therapy prevent osteosarcoma recurrence and promote wound healing after excision surgery

  • Authors   :Wang, L., Guo, H., Zhang, W., Su, Z., Huang, X.
  • Journal    : Materials Today Bio
  • Year         :2024

Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy

    • Authors   : Huang, X., Zhang, W.
    • Journal    :Small Methods
    • Year         :2024

Macrophage membrane-camouflaged biomimetic nanovesicles for targeted treatment of arthritis

  • Authors   : Huang, X., Zhang, W.
  • Journal    : Ageing Research Reviews
  • Year         :2024

The generation and use of animal models of osteosarcoma in cancer research

  • Authors   : Pu, F., Guo, H., Shi, D., Zhang, Z., Shao, Z.
  • Journal     : Genes and Diseases
  • Year         :2024

Bioinspired nanovesicles released from injectable hydrogels facilitate diabetic wound healing by regulating macrophage polarization and endothelial cell dysfunction

  • Authors   : Zhang, W., Yang, X., Huang, X., Chen, L.
  • Journal    : Journal of Nanobiotechnology
  • Year         :2023

Dr.Long Pang |Oncology Pharmaceuticals| Best Researcher Award-1332

Dr.Long Pang|Oncology Pharmaceuticals |Best Researcher Award|

Dr.Long Pang at Xi’an Medical University, China

PROFILE  

scopus

Early Academic Pursuits 📚

Long Pang was born in Gansu, China, where he developed an early passion for science and innovation. His academic journey began with a focus on veterinary science, where he pursued a Master of Science (M.S.) degree at Northwest Agricultural and Forestry University in Yangling, Shaanxi, China. Completing his M.S. in July 2012, Pang demonstrated an exceptional commitment to his studies and research in veterinary science, laying the groundwork for his future endeavors in animal biotechnology. In August 2012, he advanced his academic career by enrolling in a Ph.D. program at the same university. During his Ph.D. studies, he specialized in Animal Biotechnology, a field that encompasses the use of biotechnological tools for the improvement of animal health and productivity. He completed his Ph.D. in July 2016, marking the beginning of a promising career in biomedical research.

Professional Endeavors 🏢

After earning his Ph.D., Long Pang joined Xi’an Medical University as an Associate Professor in the School of Basic Medical Science. His professional career is distinguished by his innovative research in the areas of microfluidics and single-cell analysis. At Xi’an Medical University, Pang quickly established himself as a leading researcher, focusing on the development of microfluidic chips and their applications in single-cell analysis and organ-on-a-chip technology. His work has been instrumental in advancing the understanding of cellular mechanics and tumor microenvironments, contributing significantly to the fields of biomedical engineering and cancer research.

Contributions and Research Focus 🔬

Long Pang’s research primarily revolves around microfluidics-based single-cell analysis and organ-on-a-chip technologies. His work has led to the development of innovative microfluidic devices that allow for the manipulation and analysis of single cells in a highly controlled environment. These devices have broad applications in cancer research, particularly in studying tumor microenvironments and the behavior of cancer stem cells. One of his significant contributions includes the development of a microfluidic chip for glioma stem cell sorting and single-cell-derived tumor sphere assays. This research has provided valuable insights into the formation of tumor spheres and the role of the tumor microenvironment in cancer progression.

Pang has also been involved in projects aimed at integrating microfluidic platforms with other technologies to enhance the precision and efficiency of single-cell analysis. His research has been supported by several prestigious grants, including those from the National Science Foundation of China and the Fundamental Research Foundation of Xi’an Medical University. Notably, he has led projects such as the study of heterotypic single-cell-derived tumor-sphere formation using an integrated microfluidics platform, which has garnered significant attention and funding.

Accolades and Recognition 🏆

Long Pang’s contributions to the field of biomedical research have been widely recognized. His work has resulted in over 21 publications in high-impact journals, including TRAC-Trends in Analytical Chemistry, Analytical Chemistry, and Sensors & Actuators B: Chemical. He has also authored a chapter in the Handbook of Single-Cell Technologies, published by Springer, highlighting his expertise in digital microfluidics for single-cell manipulation and analysis. In addition to his publications, Pang has been granted two Chinese patents related to his innovations in microfluidic technology, further establishing his reputation as a leading researcher in his field.

Pang’s achievements have also been acknowledged through various editorial appointments. He has served as a Youth Editorial Board Member of Glioma and the E-Journal of Translational Medicine, where he has contributed to the advancement of research dissemination and knowledge sharing in the scientific community. His contributions to the academic community extend beyond research, as he is an active member of several professional organizations, including the Shaanxi Pharmacology Association, the Chinese Society of Micro-Nano Technology (CSMNT), and the Chinese Chemistry Society (CCS).

Impact and Influence 🌍

The impact of Long Pang’s research extends beyond academia. His work on microfluidic devices has the potential to revolutionize the way single-cell analysis is conducted, offering new tools for researchers and clinicians in the diagnosis and treatment of diseases, particularly cancer. His contributions to the development of organ-on-a-chip technology are also significant, providing a platform for more accurate and efficient drug testing, which could lead to more effective treatments for various diseases.

Pang’s research has influenced a new generation of scientists and engineers, inspiring them to explore the possibilities of microfluidics and its applications in biomedical research. His collaborations with other leading researchers and institutions, both in China and internationally, have further expanded the reach of his work, fostering innovation and knowledge exchange in the global scientific community.

Legacy and Future Contributions 🚀

Long Pang’s legacy in the field of biomedical research is characterized by his innovative approach to solving complex problems in cell biology and medicine. His contributions to the development of microfluidic technology and single-cell analysis tools have set new standards in the field, paving the way for future research and innovation. As he continues his work at Xi’an Medical University, Pang remains committed to advancing the frontiers of biomedical engineering, with a focus on developing new technologies that can improve human health and well-being.

Looking to the future, Long Pang’s ongoing research projects, such as the construction of a 3D microenvironment for single-cell level tumor cells, promise to yield further breakthroughs in our understanding of cancer and other diseases. His work is likely to continue to influence the field for years to come, as he mentors the next generation of researchers and contributes to the global effort to improve healthcare through technological innovation.

🎓Publication 

Tumor microenvironment-derived exosomes-assisted single-cell-derived tumor-sphere formation and drug-resistance by a microfluidic system

Construction of multiple concentration gradients for single-cell level drug screening

Droplets microfluidics platform—A tool for single cell research

Microfluidics-Based Single-Cell Research for Intercellular Interaction

Digital Microfluidics for Single Cell Manipulation and Analysis

  • Authors   :Pang, L., Ding, J., Fan, S.-K.
  • Journal    :Handbook of Single-Cell Technologies
  • Year         :2021